PharmaCyte Biotech, Inc.
PMCB
$1.64
-$0.12-6.82%
| 10/31/2024 | 07/31/2024 | 04/30/2024 | 01/31/2024 | 10/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -24.02% | -40.49% | 31.15% | 15.56% | -37.98% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -21.53% | -38.86% | 29.10% | 20.34% | -39.21% |
| Operating Income | 21.53% | 38.86% | -29.10% | -20.34% | 39.21% |
| Income Before Tax | -152.68% | 835.76% | 1,166.27% | 18.92% | 248.36% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -152.68% | 835.76% | 1,166.27% | 18.92% | 248.36% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -152.68% | 835.76% | 1,166.27% | 18.92% | 248.36% |
| EBIT | 21.53% | 38.86% | -29.10% | -20.34% | 39.21% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -50.39% | 586.83% | -4,184.51% | -1,524.38% | -181.84% |
| Normalized Basic EPS | 15.03% | 165.48% | 5,793.18% | -79.28% | 448.34% |
| EPS Diluted | -50.00% | 505.88% | -4,184.51% | -1,524.38% | -184.46% |
| Normalized Diluted EPS | 15.03% | 165.48% | 5,793.18% | -79.28% | 448.34% |
| Average Basic Shares Outstanding | -12.87% | -37.58% | -53.09% | -54.69% | -57.42% |
| Average Diluted Shares Outstanding | -12.87% | -37.58% | -53.09% | -54.69% | -57.42% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
